Logo image of ALTS

ALT5 SIGMA CORP (ALTS) Stock Fundamental Analysis

USA - NASDAQ:ALTS - US47089W1045 - Common Stock

3.1 USD
+0.04 (+1.31%)
Last: 9/26/2025, 6:29:50 PM
3.11 USD
+0.01 (+0.32%)
After Hours: 9/26/2025, 6:29:50 PM
Fundamental Rating

2

Taking everything into account, ALTS scores 2 out of 10 in our fundamental rating. ALTS was compared to 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALTS have multiple concerns. ALTS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALTS has reported negative net income.
ALTS had a negative operating cash flow in the past year.
ALTS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALTS reported negative operating cash flow in multiple years.
ALTS Yearly Net Income VS EBIT VS OCF VS FCFALTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

The Return On Assets of ALTS (-17.60%) is better than 62.24% of its industry peers.
ALTS has a Return On Equity (-55.73%) which is in line with its industry peers.
Industry RankSector Rank
ROA -17.6%
ROE -55.73%
ROIC N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTS Yearly ROA, ROE, ROICALTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

With a decent Gross Margin value of 47.46%, ALTS is doing good in the industry, outperforming 62.24% of the companies in the same industry.
ALTS's Gross Margin has improved in the last couple of years.
ALTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
ALTS Yearly Profit, Operating, Gross MarginsALTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

1

2. Health

2.1 Basic Checks

ALTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALTS has been increased compared to 1 year ago.
ALTS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALTS has a worse debt to assets ratio.
ALTS Yearly Shares OutstandingALTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALTS Yearly Total Debt VS Total AssetsALTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ALTS has an Altman-Z score of 2.39. This is not the best score and indicates that ALTS is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ALTS (2.39) is better than 68.88% of its industry peers.
ALTS has a Debt/Equity ratio of 0.76. This is a neutral value indicating ALTS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.76, ALTS is doing worse than 66.84% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Altman-Z 2.39
ROIC/WACCN/A
WACC9.82%
ALTS Yearly LT Debt VS Equity VS FCFALTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 0.88 indicates that ALTS may have some problems paying its short term obligations.
ALTS has a Current ratio of 0.88. This is amonst the worse of the industry: ALTS underperforms 83.67% of its industry peers.
ALTS has a Quick Ratio of 0.88. This is a bad value and indicates that ALTS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.88, ALTS is doing worse than 76.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
ALTS Yearly Current Assets VS Current LiabilitesALTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

ALTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.35%, which is quite impressive.
The Revenue has grown by 926.05% in the past year. This is a very strong growth!
The Revenue for ALTS have been decreasing by -18.62% on average. This is quite bad
EPS 1Y (TTM)74.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-799%
Revenue 1Y (TTM)926.05%
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%194.05%

3.2 Future

The Earnings Per Share is expected to grow by 28.61% on average over the next years. This is a very strong growth
ALTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 65.13% yearly.
EPS Next Y-87.54%
EPS Next 2Y-4.52%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue Next Year205.43%
Revenue Next 2Y125.77%
Revenue Next 3Y84.48%
Revenue Next 5Y65.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALTS Yearly Revenue VS EstimatesALTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
ALTS Yearly EPS VS EstimatesALTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTS Price Earnings VS Forward Price EarningsALTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTS Per share dataALTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as ALTS's earnings are expected to grow with 28.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.52%
EPS Next 3Y28.61%

More info and screens

0

5. Dividend

5.1 Amount

ALTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALT5 SIGMA CORP

NASDAQ:ALTS (9/26/2025, 6:29:50 PM)

After market: 3.11 +0.01 (+0.32%)

3.1

+0.04 (+1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners7.96%
Inst Owner Change0%
Ins Owners4.19%
Ins Owner Change0%
Market Cap380.09M
Analysts82.86
Price Target24.48 (689.68%)
Short Float %6.24%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-101.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.08
P/FCF N/A
P/OCF N/A
P/B 12.71
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.18
BVpS0.24
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.6%
ROE -55.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.46%
FCFM N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z 2.39
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-799%
EPS Next Y-87.54%
EPS Next 2Y-4.52%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue 1Y (TTM)926.05%
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%194.05%
Revenue Next Year205.43%
Revenue Next 2Y125.77%
Revenue Next 3Y84.48%
Revenue Next 5Y65.13%
EBIT growth 1Y2.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.41%
EBIT Next 3Y44.5%
EBIT Next 5Y44.66%
FCF growth 1Y-57.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.27%
OCF growth 3YN/A
OCF growth 5YN/A